Previous close | 2.4000 |
Open | 2.5000 |
Bid | 2.9600 |
Ask | 3.0000 |
Strike | 35.00 |
Expiry date | 2024-01-19 |
Day's range | 2.4500 - 2.9900 |
Contract range | N/A |
Volume | |
Open interest | 44.08k |
Stock valuations are at historically high levels. Three Motley Fool contributors identified bargain stocks to buy in a market that's priced for perfection. Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE).
Dividends are great. They're a reliable source of passive income for retirees (and others) or can help boost long-term returns for investors who choose to reinvest them. But what happens when a company decreases or suspends its payouts? No investor wants to run into this problem.
The Food and Drug Administration (FDA) just approved the updated Omicron-adapted COVID-19 booster shots from Moderna (NASDAQ: MRNA) and the COVID-19 booster that Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) collaborated on. While the news will certainly help the pharmaceutical companies' bottom lines, it's important to look deeper to see if any of these three stocks make a solid investment today. At first glance, Pfizer's stock appears to be a screaming deal.